Prostate-Specific Membrane Antigen-Based PET Brings New Insights into the Management of Prostate Cancer

Cong Hu,Liang Dong,Wei Xue,Kenneth J. Pienta

DOI: https://doi.org/10.1016/j.cpet.2022.07.001

2022-01-01

PET Clinics

Abstract:Prostate cancer (PCa) is the third most common cancer diagnosed in the world. Since its first identification in 1987 and its first molecular cloning in 1993, prostate-specific membrane antigen (PSMA) has been developed as a theragnostic imaging biomarker and therapeutic agent for PCa. For metastatic castration-resistant PCa, PSMA-based PET imaging can be applied to the monitoring of disease and response assessment with PSMA-based therapeutics. This novel imaging modality is bringing new insights into diagnosis, stratification, and clinical decision-making and treatment.